Two reports describe patients suffering from a low-grade glioma (LGG), one with a NACC2:NTRK fusion showing more than 50% reduction in tumor volume and an ETV6:NTRK3-fused tumor with complete remission upon treatment with larotrectinib [8,31]. This evidence concerns the gene ETV6 and neoplasm.